NEUROMYELITIS OPTICA SPECTRUM DISORDER

Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER explained in plain language.

Never miss a new study

Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER trials appear

Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 7 Not yet finished but already full! 5 Completed 1

Breakthrough drug shows promise in halting debilitating neurological attacks

Disease control Completed

This Phase 3 clinical trial tested whether the drug ravulizumab could safely prevent relapses in adults with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the spinal cord and optic nerves. The study involved 58 participants and compared ou…

Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER

Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

NEUROMYELITIS OPTICA SPECTRUM DISORDER

Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER trials appear

Breakthrough drug shows promise in halting debilitating neurological attacks